Spin-off company based in the eastern part of Poland offers innovative, implantable biomaterial for effective treatment of bone defects. The product (the so-called "artificial bone") is dedicated for traumatic surgery, orthopaedics, craniofacial and veterinary surgery. The main advantages for users are surgical handiness, high specific surface area and high ability to absorb.
The company is looking for distributors.
Cooperation plus value:
The main individual features of company's product are as follows:
Surgical handiness, which allows to adjust it during surgery to the shape of individual bone defects by cutting or bending. In a dry state, material can be milled which enables the personalization of the composite implant. High specific surface area (due to the high microporosity of granules), high ionic reactivity (adsorption of calcium and phosphate ions from surroundings liquid which allows to increase the rate of mineralization. Application of carbohydrate polymer to produce the material composite minimizes the risk of viruses and prions contamination. Curdlan undegoes gelling, forming the structure of irreversible, collagen-like triple helix – the conformation which is neutral for macrophages and does not evoke the appearance of local inflammation. The product has exhibit high soaking capacity and can be easily stored and transported.
Cooperation stage dev stage:
The partner's role as a distributor should be responsibility for sale and distribution of the biomaterial to the hospitals, private clinics. An advantage would be if the partner has contacts with the hospitals.
Dissemination sector group :
Dissemination preferred :
Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Moldova, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom